Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05624528 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 4 more changesShow less
    • Results posted: Sep 23, 2026
    • Trial completed
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Secondary endpoints revised (4)v14
  3. Enrollment target: 300 to 49
    • Secondary endpoints revised (4)
    v13
  4. Enrollment target: 49 to 300v12 Show 4 more changesShow less
    • Primary endpoint revised
    • Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Jun 2026 to Jun 1, 2026
    • Secondary endpoints revised (4)
  5. Re-verified, no change to tracked fieldsv11
Show 9 earlier versionsHide 9 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 85 to confirmed 49
    • Site details revised
    v10
  2. Primary completion date: Dec 2025 to Jun 2026
    • Study completion date: Jan 2026 to Jun 2026
    v9
  3. Primary completion date: Jun 2025 to Dec 2025
    • Study completion date: Jul 2025 to Jan 2026
    v8
  4. 2 versions Re-verified since Aug 7, 2024, no change to tracked fieldsv6-v7
  5. Site contact updatedv5
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2023 to Jun 22, 2023
    v4
  7. Re-verified, no change to tracked fieldsv3
  8. Start date: Feb 2023 to Jun 2023
    • Primary completion date: Feb 2025 to Jun 2025
    • Study completion date: Mar 2025 to Jul 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Chicago
307 trials monitored
See 12 trials at risk
Anxiety
3,263 trials monitored
See 159 trials at risk
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
Trial Details
NCT Number NCT05624528
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Obsessive-Compulsive Disorder, OCD
Related terms Obsessive-Compulsive Disorder
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov